Drug Type CAR-T |
Synonyms- |
Target |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | CN | - | |
Liver Cancer | Phase 2 | CN | - | |
Esophageal Carcinoma | Preclinical | CN | 01 Sep 2019 | |
Glioma | Preclinical | CN | 01 Sep 2019 | |
Hepatocellular Carcinoma | Preclinical | CN | 01 Sep 2019 | |
Stomach Cancer | Preclinical | CN | 01 Sep 2019 |